Cytoprotective effects of hydrogen sulfide in novel rat models of non-erosive esophagitis

PLoS ONE

Volumn 9, Issue 10, 2014, Pages

  Zayachkivska, Oksana ^a   Havryluk, Olena ^a   Hrycevych, Nazar ^a   Bula, Nazar ^a   Grushka, Oksana ^a   Wallace, John L ^b  

^a DANYLO HALYTSKY LVIV NATIONAL MEDICAL UNIVERSITY   (Ukraine)

^b UNIVERSITY OF CALGARY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

HYDROGEN SULFIDE; INTERLEUKIN 10; INTERLEUKIN 7; TRYPTOPHAN; IL10 PROTEIN, HUMAN; IL17A PROTEIN, HUMAN; INTERLEUKIN 17;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BASAL CELL; CELL HYPERPLASIA; CELL PROTECTION; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG EFFECT; DRUG MECHANISM; EDEMA; ESOPHAGITIS; ESOPHAGUS DISEASE; HISTOPATHOLOGY; HYPERGLYCEMIA; MALE; MONOTHERAPY; MORPHOLOGY; MUCOSAL IMMUNITY; NEUTROPHIL CHEMOTAXIS; NON EROSIVE ESOPHAGITIS; NONHUMAN; PROTEIN BLOOD LEVEL; RAT; SUBMUCOSAL ESOPHAGEAL EDEMA; WATER IMMERSION; ANIMAL; BLOOD; DISEASE MODEL; DRUG EFFECTS; GASTROESOPHAGEAL REFLUX; HUMAN; PATHOLOGY;

RATTUS;

ANIMALS; CYTOPROTECTION; DISEASE MODELS, ANIMAL; ESOPHAGITIS; GASTROESOPHAGEAL REFLUX; HUMANS; HYDROGEN SULFIDE; INTERLEUKIN-10; INTERLEUKIN-17; RATS;

EID: 84908180956     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0110688     Document Type: Article

References (61)

1. Konturek SJ, Zayachkivska O, Havryluk XO, Brzozowski T, Sliwowski Z, et al. (2007) Protective influence of melatonin against acute esophageal lesions involves prostaglandins, nitric oxide and sensory nerves. Journal of Physiology and Pharmacology 58: 361-377.
2. Modlin IM, Hunt RH, Malfertheiner P, Moayyedi P, Quigley EM, et al. (2009) Diagnosis and management of non-erosive reflux disease-the Vevey NERD Consensus Group. Digestion 80: 74-88.
3. Promberger R, Lenglinger J, Riedl O, Seebacher G, Eilenberg W, et al. (2014) Gastro-oesophageal reflux disease in type 2 diabetics: symptom load and pathophysiologic aspects - a retro-pro study. BMC Gastroenterology 14: 132.
4. Kandulski A, Malfertheiner P (2012) Gastroesophageal reflux disease-from reflux episodes to mucosal inflammation. Nature Reviews Gastroenterology & hepatology 9: 15-22.
5. Kinekawa F, Kubo F, Matsuda K, Kobayashi M, Furuta Y, et al. (2008) Esophageal function worsens with long duration of diabetes. Journal of Gastroenterology 43: 338-344.
6. Zayachkivska OS, Hzhehots'kyi MR, Kovalyshyn VI (2005) [Oral and gastric diffuse neuroendocrine system: discussion questions of structure and function]. Fiziol Zh 51: 79-90.
7. Langner C, Schneider NI, Plieschnegger W, Schmack B, Bordel H, et al. (2014) Cardiac mucosa at the gastro-oesophageal junction: indicator of gastrooesophageal reflux disease? Data from a prospective central European multi-centre study on histological and endoscopic diagnosis of oesophagitis (histoGERD trial). Histopathology 65: 81-89.
8. Long JD, Orlando RC (2007) Nonerosive reflux disease. Minerva gastroenterologica e dietologica 53: 127-141.
9. Savarino E, Zentilin P, Mastracci L, Dulbecco P, Marabotto E, et al. (2013) Microscopic esophagitis distinguishes patients with non-erosive reflux disease from those with functional heartburn. Journal of Gastroenterology 48: 473-482.
10. Blackett KL, Siddhi SS, Cleary S, Steed H, Miller MH, et al. (2013) Oesophageal bacterial biofilm changes in gastro-oesophageal reflux disease, Barrett's and oesophageal carcinoma: association or causality? Alimentary Pharmacology & Therapeutics 37: 1084-1092.
11. Mastrocola R, Collino M, Rogazzo M, Medana C, Nigro D, et al. (2013) Advanced glycation end products promote hepatosteatosis by interfering with SCAP-SREBP pathway in fructose-drinking mice. American Journal of Physiology Gastrointestinal and Liver physiology 305: G398-G407.
12. Miyashita T, Shah FA, Miwa K, Sasaki S, Nishijima K, et al. (2013) Impact of inflammation-metaplasia-adenocarcinoma sequence and prevention in surgical rat models. Digestion 87: 6-11.
13. Nishida T, Tsuji S, Tsujii M, Arimitsu S, Sato T, et al. (2004) Gastroesophageal reflux disease related to diabetes: Analysis of 241 cases with type 2 diabetes mellitus. Journal of Gastroenterology and Hepatology 19: 258-265.
14. Blackler R, Syer S, Bolla M, Ongini E, Wallace JL (2012) Gastrointestinal-sparing effects of novel NSAIDs in rats with compromised mucosal defence. PLoS One 7: e35196.
15. Li Q, Winston JH, Sarna SK (2013) Developmental origins of colon smooth muscle dysfunction in IBS-like rats. American Journal of Physiology Gastrointestinal and Liver physiology 305: G503-G512.
16. Novosad VL, Richards JL, Phillips NA, King MA, Clanton TL (2013) Regional susceptibility to stress-induced intestinal injury in the mouse. American Journal of Physiology Gastrointestinal and Liver Physiology 305: G418-G426.
17. Zayachkivska O, Gzregotsky M, Ferentc M, Yaschenko A, Urbanovych A (2008) Effects of nitrosative stress and reactive oxygen-scavenging systems in esophageal physiopathy under streptozotocin-induced experimental hyperglycemia. Journal of physiology and pharmacology: an official journal of the Polish Physiological Society 59 Suppl 2: 77-87.
18. Soderholm JD (2007) Stress-related changes in oesophageal permeability: filling the gaps of GORD? Gut 56: 1177-1180.
19. Wu YC, Wang XJ, Yu L, Chan FK, Cheng AS, et al. (2012) Hydrogen sulfide lowers proliferation and induces protective autophagy in colon epithelial cells. PLoS One 7: e37572.
20. Sellin JH, Chang EB (2008) Therapy Insight: gastrointestinal complications of diabetes-pathophysiology and management. Nature Clinical Practice Gastroenterology & Hepatology 5: 162-171.
21. Wu P, Ma L, Dai GX, Chen Y, Tong YL, et al. (2011) The association of metabolic syndrome with reflux esophagitis: a case-control study. Neurogastroenterology and Motility 23: 989-994.
22. Goldberg RB (2009) Cytokine and cytokine-like inflammation markers, endothelial dysfunction, and imbalanced coagulation in development of diabetes and its complications. The Journal of Clinical Endocrinology and Metabolism 94: 3171-3182.
23. Hrynevych N, Zayachkivska O, Yaschenko A (2013). Effect of L-tryptophan on cytoprotection against long-term postprandial hyperglycemia-induced esophageal damage in rats. FASEB J, 27: 1169.2.
24. Zayachkivska O, Savytska M, Pinyajko R, Gzhegotsky M (2009). Esophageal structural and functional reorganisation: role of endogenous defense mediators. Journal of Physiological Sciences 59: 389-338.
25. Szabo C (2009) Role of nitrosative stress in the pathogenesis of diabetic vascular dysfunction. British Journal of Pharmacology 156: 713-727.
26. Wallace JL, Caliendo G, Santagada V, Cirino G, Fiorucci S (2007) Gastrointestinal safety and anti-inflammatory effects of a hydrogen sulfide-releasing diclofenac derivative in the rat. Gastroenterology 132: 261-271.
27. Wallace JL, Caliendo G, Santagada V, Cirino G (2010) Markedly reduced toxicity of a hydrogen sulphide-releasing derivative of naproxen (ATB-346). British Journal of Pharmacology 159: 1236-1246.
28. Wallace JL, Blackler RW, Chan MV, Da Silva GJ, Elsheikh W, et al. (2014) Anti-Inflammatory and cytoprotective actions of hydrogen sulfide: translation to therapeutics. Antioxidants & Redox Signaling, in press.
29. Mard SA, Neisi N, Solgi G, Hassanpour M, Darbor M, et al. (2012) Gastroprotective effect of NaHS against mucosal lesions induced by ischemia-reperfusion injury in rat. Digestive Diseases and Sciences 57: 1496-1503.
30. Wallace JL (2007) Hydrogen sulfide-releasing anti-inflammatory drugs. Trends in Pharmacological Sciences 28: 501-505.
31. Flannigan KL, Ferraz JG, Wang R, Wallace JL (2013) Enhanced synthesis and diminished degradation of hydrogen sulfide in experimental colitis: a site-specific, pro-resolution mechanism. PLoS One 8: e71962.
32. Kimura H, Shibuya N, Kimura Y (2012) Hydrogen sulfide is a signaling molecule and a cytoprotectant. Antioxidants & Redox Signaling 17: 45-57.
33. Wang R (2012) Physiological implications of hydrogen sulfide: a whiff exploration that blossomed. Physiological Reviews 92: 791-896.
34. Wallace JL, Dicay M, McKnight W, Martin GR (2007) Hydrogen sulfide enhances ulcer healing in rats. FASEB J 21: 4070-4076.
35. Wallace JL, Vong L, McKnight W, Dicay M, Martin GR (2009) Endogenous and exogenous hydrogen sulfide promotes resolution of colitis in rats. Gastroenterology 137: 569-578.
36. Kozar VV, Kudria MY, Ustenko NV, Pavlenko TO, Zhurakovska MV (2009) The state of the humoral component of immunity under conditions of metabolic syndrome with underlying hypoestrogenia and its farmacological correction. [in Ukrainian]. Buk Med Herald 13: 141-144.
37. Takagi K, Kasuya Y, Watanabe K (1964) Studies on the drugs for peptic ulcer. A reliable method for producing stress ulcer in rats. Chemical & pharmaceutical Bulletin 12: 465-472.
38. Fiorucci S, Antonelli E, Distrutti E, Rizzo G, Mencarelli A, et al. (2005) Inhibition of hydrogen sulfide generation contributes to gastric injury caused by anti-inflammatory nonsteroidal drugs. Gastroenterology 129: 1210-1224.
39. Papapetropoulos A, Pyriochou A, Altaany Z, Yang G, Marazioti A, et al. (2009) Hydrogen sulfide is an endogenous stimulator of angiogenesis. Proceedings of the National Academy of Sciences USA 106: 21972-21977.
40. Takeuchi K, Aihara E, Kimura M, Dogishi K, Hara T, et al. (2012) Gas mediators involved in modulating duodenal HCO3(-) secretion. Current Medicinal Chemistry 19: 43-54.
41. Blackler RW, Gemici B, Manko A, Wallace JL (2014) NSAID-gastroenterop-athy: new aspects of pathogenesis and prevention. Current Opinion in Pharmacology 19C: 11-16.
42. Motta JP, Blackler R, Workentine M, da Silva G, Buret A, et al. (2014) Hydrogen sulfide alters gut bacterial growth and diversity, and stimulates host mucosal immunity. Canadian Journal of Gastroenterology & Hepatology 28 (suppl SA), 88A.
43. Zanardo RC, Brancaleone V, Distrutti E, Fiorucci S, Cirino G, et al. (2006) Hydrogen sulfide is an endogenous modulator of leukocyte-mediated inflammation. FASEB J 20: 2118-2120.
44. Kimura Y, Goto Y, Kimura H (2010) Hydrogen sulfide increases glutathione production and suppresses oxidative stress in mitochondria. Antioxidants & Redox Signaling 12: 1-13.
45. Mariggio MA, Minunno V, Riccardi S, Santacroce R, De Rinaldis P, et al. (1998) Sulfide enhancement of PMN apoptosis. Immunopharmacology and Immunotoxicology 20: 399-408.
46. Dufton N, Natividad J, Verdu EF, Wallace JL (2012) Hydrogen sulfide and resolution of acute inflammation: A comparative study utilizing a novel fluorescent probe. Scientific Reports 2: 499.
47. Bai AP, Ouyang Q, Hu RW (2005) Diallyl trisulfide inhibits tumor necrosis factor-alpha expression in inflamed mucosa of ulcerative colitis. Digestive Diseases and Sciences 50: 1426-1431.
48. Fiorucci S, Orlandi S, Mencarelli A, Caliendo G, Santagada V, et al. (2007) Enhanced activity of a hydrogen sulphide-releasing derivative of mesalamine (ATB-429) in a mouse model of colitis. British Journal of Pharmacology 150: 996-1002.
49. Li L, Rossoni G, Sparatore A, Lee LC, Del Soldato P, et al. (2007) Anti-inflammatory and gastrointestinal effects of a novel diclofenac derivative. Free Radical Biology & Medicine 42: 706-719.
50. Flannigan KL, Agbor TA, Blacker RW, Kim JJ, Khan WI, et al. (2014) Impaired hydrogen sulfide synthesis and IL-10 signaling underlie hyperhomocysteinemia-associated exacerbation of colitis. Proceedings of the National Academy of Science USA 111: 13559-13564.
51. Mirandola P, Gobbi G, Micheloni C, Vaccarezza M, Di Marcantonio D, et al. (2011) Hydrogen sulfide inhibits IL-8 expression in human keritanocytes via MAP kinase signaling. Laboratory Investigation 91: 1188-1194.
52. Hymowitz SG, Filvaroff EH, Yin JP, Lee J, Cai L, et al. (2001) IL-17s adopt a cystine knot fold: structure and activity of a novel cytokine IL-17F, and implications for receptor binding. EMBO Journal 20: 5332-5341.
53. Asimakopoulou A, Panopoulos P, Chasapis CT, Coletta C, Zhou Z, et al. (2013) Selectivity of commonly used pharmacological inhibitors for cystathionine beta synthase (CBS) and cystathionine gamma lyase (CSE). British Journal of Pharmacology 169: 922-932.
54. Hershcovici T, Jha LK, Gadam R, Cui H, Gerson L, et al. (2012) The relationship between type 2 diabetes mellitus and failure to proton pump inhibitor treatment in gastroesophageal reflux disease. Journal of Clinical Gastroenterology 46: 662-668.
55. Zhang Q, Horowitz M, Rigda R, Rayner C, Worynski A, et al. (2004) Effect of hyperglycemia on triggering of transient lower esophageal sphincter relaxations. American Journal of Physiology Gastrointestinal and Liver physiology 286: G797-G803.
56. Wolin MS (2009) Reactive oxygen species and the control of vascular function. American Journal of Physiology Heart and Circulatory Physiology 296: H539-H549.
57. Zayachkivska O (2012) Physiopathology of esophageal inflammation, ulcerogenesis and repair by studying the profile of glycoconjugate. Cell/Tissue Injury and Cytoprotection/Organoprotection in the Gastrointestinal Tract: Mechanisms, Prevention and Treatment. Filaretova LP, Takeuchi K (eds): Frontiers of Gastrointestinal Research. Basel, Karger 30: 148-160.
58. Zayachkivska OC (2006) Significance of NO-mediated mechanism in resistance of esophageal mucosa. Ukr Medical Almanac 9: 48-49.
59. Zayachkivska O, Hrycevych N, Zvir M (2010) Effect of proinflammatory cytokine-mediated mechanism of quality of gastrointestinal restitutio ad integrum. Annales Universitatis Mariae Curie-Skłodowska 28 (Suppl. 8): 211-214.
60. Altaany Z, Moccia F, Munaron L, Mancardi D, Wang R (2014) Hydrogen sulfide and endothelial dysfunction: relationship with nitric oxide. Current Medicinal Chemistry, in press.
61. Chan MV, Wallace JL (2013) Hydrogen sulfide-based therapeutics and gastrointestinal diseases: translating physiology to treatments. American Journal of Physiology Gastrointestinal and Liver Physiology 305: G467-G473.